Maurice Stroun

Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

Retrieved on: 
Thursday, January 14, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Medicine, Clinical medicine, Branches of biology, Genomics, Helmy Eltoukhy, Liquid biopsy, Biopsy, Cancer, Richard B. Lanman, Maurice Stroun

The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.

Key Points: 
  • The presentations will cover the use of Guardant Healths liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.
  • It is increasingly becoming evident that the value of our liquid biopsy in advanced cancer extends beyond simply tumor mutation profiling.
  • The data presented further demonstrates the value of assessing molecular response to treatment, ushering in a new age of adaptive management of disease progression, said Helmy Eltoukhy, Guardant Health CEO.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients.

Bluestar Genomics to Share New Noninvasive Data for Earlier Cancer Detection at 11th CNAPs International Symposium

Retrieved on: 
Tuesday, September 24, 2019
Research, Other Health, General Health, Oncology, Genetics, Science, Biotechnology, Other Science, Health, Chemistry, Natural sciences, Physical sciences, DNA, Laboratory techniques, Blue star, Circulating free DNA, Assay, Maurice Stroun

Bluestar Genomics Chief Scientific Officer, Samuel Levy, PhD, will be presenting at the 11th CNAPs International Symposium on Circulating Nucleic Acids in Plasma & Serum on September 23 through 25 in Jerusalem, Israel.

Key Points: 
  • Bluestar Genomics Chief Scientific Officer, Samuel Levy, PhD, will be presenting at the 11th CNAPs International Symposium on Circulating Nucleic Acids in Plasma & Serum on September 23 through 25 in Jerusalem, Israel.
  • At Bluestar Genomics we are developing a novel blood test and we look forward to demonstrating superior predictability for detection of earlier stage cancers.
  • By monitoring 5hmC profiles in cell-free DNA (cfDNA) Bluestar Genomics is able to detect the presence of cancer from a simple blood sample.
  • The platform technology at Bluestar Genomics shows how the detection of the presence of cancer and concordant classification of tumor origin can be leveraged toward a robust clinical assay for routine cancer detection, said Dr. Levy.